Insight Molecular Diagnostics Inc.
IMDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001642380
No open-market purchases or sales by Insight Molecular Diagnostics Inc. insiders were filed in the last 90 days; 40 institutions reported holding it in 13F filings for Q2 2026, worth $108.9M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Insight Molecular Diagnostics Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 30 | 26 | −4 |
| Shares | 4.55M | 4.45M | −102.6K (−2.3%) |
| Value | $14.3M | $11.1M | −$3.22M (−22.5%) |
New holders (1)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Coppell Advisory Solutions LLC | 10 | $25 | 0.00% |
Sold out (5)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Millennium Management LLC | 14,754 | $48.4K |
| US Bancorp | 25 | $78 |
| Meeder Asset Management Inc | 9 | $28 |
| NBC Securities, Inc. | 150 | $0 |
| Capital Advisors, Ltd. LLC | 61 | $0 |